EX-FILING FEES 2 xene-exfilingfees_10.htm EX-FILING FEES xene-exfilingfees_10.htm

Exhibit 107

 

Calculation of Filing Fee Tables

424(b)(5)
(Form Type)

Xenon Pharmaceuticals Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

 

Security Type

Security Class Title

Fee Calculation or Carry Forward Rule

Amount Registered

Proposed Maximum Offering Price Per Unit

Maximum Aggregate Offering Price

Fee Rate

Amount of Registration Fee

Carry Forward Form Type

Carry Forward File Number

Carry Forward Initial effective date

Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward

Newly Registered Securities

Fees to Be Paid

Equity

Common Shares, no par value per share

457(r)

9,426,230(2)

$30.50

$287,500,015

$92.70 per $1,000,000

 

$26,651.25

 

 

 

 

Fees to Be Paid

Equity

Pre-funded warrants to purchase common shares(3)

Other

327,868

$30.4999(4)

(5)

(5)

(5)

 

 

 

 

Fees Previously Paid

Carry Forward Securities

Carry Forward Securities

 

 

Total Offering Amounts

 

$287,500,015

 

$26,651.25(1)

 

 

 

 

 

Total Fees Previously Paid

 

 

 

 

 

 

 

 

Total Fee Offsets

 

 

 

 

 

 

 

 

Net Fee Due

 

 

 

$26,651.25

 

 

 

 

 

 

(1)

This filing fee is calculated and being paid pursuant to Rule 457(r) of the Securities Act of 1933, as amended (the “Securities Act”), and relates to our Registration Statement on Form S-3ASR (File No. 333-260010).

 

(2)

Includes 1,229,508 common shares issuable upon exercise of the underwriters’ option to purchase additional common shares and 327,868 common shares issuable upon the exercise of the pre-funded warrants referenced below.

 

(3)

Pursuant to Rule 416 under the Securities Act, the pre-funded warrants to purchase common shares being registered hereunder include such indeterminate number of additional common shares as may be issued after the date hereof as a result of share splits, share dividends or similar transactions.

 

(4)

The purchase price is $30.4999 per pre-funded warrant to purchase common shares (which equals the public offering price per common share less the $0.0001 per share exercise price of each such pre-funded warrant).

 

(5)

Pursuant to Securities and Exchange Commission staff interpretation, the entire fee is allocated to the common shares underlying